Kura Oncology Inc (KURA)

Kura Oncology Inc (KURA) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $944M; returns 1 day -2.5%, 1 week +5.8%, 1 year +5.6%.

Kura Oncology, Inc. is a biopharmaceutical company focused on developing precision medicines for cancer. It has recently transitioned from a clinical-stage to a commercial-stage company following the U.S. FDA approval of its lead drug, KOMZIFTI™ (ziftomenib), in November 2025.

Groups KURA belongs to

• Healthcare
• Biotechnology
• Biopharmaceutical
• Oncology
• Commercial Stage
• Commercial Stage Biotech
• Cancer Therapeutics
• Precision Medicine
• Hematologic Malignancies
• Hematology
• Pharmaceuticals
• Life Sciences
• Strategic Partnerships

KURA financial model: income statement, cash flow and balance sheet